Insight Molecular Diagnostics (IMDX) vs Precipio (PRPO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precipio (PRPO) has outperformed Insight Molecular Diagnostics (IMDX) over the past year, gaining 26.4% versus a loss of 10.9%. Over five years, PRPO leads with a -54.7% price change compared with -95.2% for IMDX. Insight Molecular Diagnostics is the larger company by market cap ($107.3 million vs $41.5 million), about 2.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMDX | PRPO |
|---|---|---|
| Share price | $3.28 | $23.19 |
| Market cap | $107.34M | $41.51M |
| 1-day change | -5.20% | -1.40% |
| YTD return | -56.27% | +0.91% |
| 1-year return | -10.87% | +26.38% |
| 5-year return | -95.18% | -54.71% |
| Forward P/E | — | 59.46 |
| EPS (TTM) | $-1.52 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.51 | $33.63 |
| 52-week low | $2.42 | $16.40 |
| Distance from 52-week high | -61.46% | -31.04% |
| Analyst consensus | none | — |
| Avg. price target upside | +151.52% | — |
| Average volume | 232.87K | 128.13K |
| Shares outstanding | 32.72M | 1.79M |
| Employees | 55 | 61 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Insight Molecular Diagnostics is about 2.6 times larger than Precipio by market value ($107.34M vs $41.51M).
- PRPO has outperformed IMDX by 37.2 percentage points over the past year.
- The two companies sit in different sectors: Insight Molecular Diagnostics in Health Care and Precipio in Industrials.
About Insight Molecular Diagnostics
IMDX stock →Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 55 employees
About Precipio
PRPO stock →Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 61 employees
IMDX vs PRPO FAQ
Which is bigger, Insight Molecular Diagnostics or Precipio?
Insight Molecular Diagnostics (IMDX) is larger, with a market capitalization of $107.34M compared with $41.51M for Precipio (PRPO).
Which stock has performed better over the past year, IMDX or PRPO?
PRPO returned +26.38% over the past 12 months, compared with -10.87% for IMDX (price return, excluding dividends). Past performance does not predict future results.
Are Insight Molecular Diagnostics and Precipio in the same industry?
No. Insight Molecular Diagnostics is in the Health Care sector, while Precipio is in Industrials.